Dr. Reddy's Laboratories Ltd (NYSE:RDY - Get Free Report) has been assigned a consensus recommendation of "Hold" from the six ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $492.90.
A number of research analysts have commented on the company. JPMorgan Chase & Co. upgraded Dr. Reddy's Laboratories from an "underweight" rating to a "neutral" rating in a research note on Monday, October 26th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Dr. Reddy's Laboratories in a research note on Wednesday, October 21st. Jefferies Financial Group raised Dr. Reddy's Laboratories from an "underperform" rating to a "hold" rating and set a $13.90 price target for the company in a research note on Sunday, October 25th. BNP Paribas Exane upgraded Dr. Reddy's Laboratories to an "outperform" rating and set a $14.80 price target for the company in a report on Monday, October 12th. Finally, Citigroup raised Dr. Reddy's Laboratories from a "sell" rating to a "buy" rating and boosted their price target for the company from $1,040.00 to $1,450.00 in a research note on Tuesday, September 29th.
Check Out Our Latest Research Report on Dr. Reddy's Laboratories
Institutional Trading of Dr. Reddy's Laboratories
Large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. lifted its stake in shares of Dr. Reddy's Laboratories by 54.8% in the 3rd quarter. Goldman Sachs Group Inc. now owns 1,630,395 shares of the company's stock valued at $20,576,000 after purchasing an additional 576,908 shares during the last quarter. Aikya Investment Management Ltd boosted its holdings in Dr. Reddy's Laboratories by 6.8% in the third quarter. Aikya Investment Management Ltd now owns 9,068,536 shares of the company's stock worth $114,445,000 after purchasing an additional 574,684 shares in the last quarter. Royal Bank of Canada increased its position in Dr. Reddy's Laboratories by 4.6% during the first quarter. Royal Bank of Canada now owns 9,984,082 shares of the company's stock worth $138,293,000 after buying an additional 434,805 shares during the last quarter. Jump Financial LLC increased its position in Dr. Reddy's Laboratories by 273.3% during the third quarter. Jump Financial LLC now owns 389,000 shares of the company's stock worth $4,909,000 after buying an additional 284,800 shares during the last quarter. Finally, Quantinno Capital Management LP increased its position in Dr. Reddy's Laboratories by 71.2% during the first quarter. Quantinno Capital Management LP now owns 637,094 shares of the company's stock worth $8,824,000 after buying an additional 264,856 shares during the last quarter. 3.85% of the stock is owned by institutional investors.
Dr. Reddy's Laboratories Stock Up 1.3%
RDY stock opened at $14.98 on Thursday. The company has a 50 day moving average of $13.22 and a two-hundred day moving average of $13.30. The company has a market cap of $12.51 billion, a price-to-earnings ratio of 40.49, a PEG ratio of 3.06 and a beta of 0.31. Dr. Reddy's Laboratories has a 12-month low of $11.36 and a 12-month high of $15.67. The company has a quick ratio of 1.40, a current ratio of 1.93 and a debt-to-equity ratio of 0.03.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its quarterly earnings results on Saturday, October 24th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.10 by $0.02. Dr. Reddy's Laboratories had a net margin of 8.56% and a return on equity of 7.91%. The business had revenue of $903.89 million for the quarter, compared to analysts' expectations of $894.94 million. On average, equities analysts anticipate that Dr. Reddy's Laboratories will post 0.46 earnings per share for the current fiscal year.
About Dr. Reddy's Laboratories
(
Get Free Report)
Dr. Reddy's Laboratories is an India-based pharmaceutical company that develops, manufactures and markets generic medicines, active pharmaceutical ingredients (APIs) and other healthcare products. Its portfolio includes branded and unbranded generics, biosimilars and select proprietary medicines across therapeutic areas such as oncology, gastroenterology, cardiovascular care and diabetes. Founded in 1984 by Kallam Anji Reddy, the company is headquartered in Hyderabad, India. It serves patients and customers in India and international markets, including the United States, Europe and countries in Russia and the Commonwealth of Independent States.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.